Cargando…

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer

BACKGROUND: Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA and BECOX) to determine if hypertension and proteinuria predict outcome in elderly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feliu, Jaime, Salud, Antonieta, Safont, Maria J., García-Girón, Carlos, Aparicio, Jorge, Losa, Ferran, Bosch, Carlos, Escudero, Pilar, Casado, Enrique, Jorge, Monica, Bohn, Uriel, Pérez-Carrión, Ramon, Carmona, Alberto, Custodio, Ana B., Maurel, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300229/ https://www.ncbi.nlm.nih.gov/pubmed/25602286 http://dx.doi.org/10.1371/journal.pone.0116527

Ejemplares similares

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
por: Salazar, Ramon, et al.
Publicado: (2015)

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
por: Salazar, Ramón, et al.
Publicado: (2020)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)
por: García‐Albéniz, Xabier, et al.
Publicado: (2019)

Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
por: Saloustros, Emmanouil, et al.
Publicado: (2010)

Effect of a Single Intravitreal Bevacizumab Injection on Proteinuria in Patients With Diabetes
por: Chung, Yoo-Ri, et al.
Publicado: (2020)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab
por: Hanna, Ramy M, et al.
Publicado: (2020)

A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) Study
por: Aparicio, Jorge, et al.
Publicado: (2014)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
por: Okuno, Keisuke, et al.
Publicado: (2023)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Proteinuria in COVID-19
por: Mohamed, Muner M B, et al.
Publicado: (2021)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2006)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Understanding the Mechanisms of Proteinuria: Therapeutic Implications
por: Toblli, Jorge E., et al.
Publicado: (2012)

Terahertz spectra of proteinuria and non-proteinuria
por: Xue, Zhenrui, et al.
Publicado: (2023)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Seroprevalence of Angiostrongylus cantonensis in Wild Rodents from the Canary Islands
por: Martin-Alonso, Aarón, et al.
Publicado: (2011)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
por: Codony-Servat, Jordi, et al.
Publicado: (2017)

Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis
por: Zhao, Tingting, et al.
Publicado: (2017)

Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study
por: Bagheri, Sina, et al.
Publicado: (2018)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2020)

Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study
por: Dote, Satoshi, et al.
Publicado: (2023)

Albumin-to-protein ratio in spot urine samples for analysis of proteinuria selectivity in chronic kidney disease
por: Pereira, Miguel Augusto Martins, et al.
Publicado: (2022)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

Bevacizumab-induced proteinuria and its association with antihypertensive drugs: A retrospective cohort study using a Japanese administrative database
por: Kiyomi, Anna, et al.
Publicado: (2023)

Proteinuria in Diabetes
por: Thomas, Stephen, et al.
Publicado: (2000)

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study
por: Vera, Ruth, et al.
Publicado: (2020)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

Role of the podocyte in proteinuria
por: Menzel, Sylvia, et al.
Publicado: (2011)

Progress in Pathogenesis of Proteinuria
por: Zhang, Aihua, et al.
Publicado: (2012)

Adult orthostatic proteinuria
por: Uehara, Keita, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_644oj4k0pbo1ehuk05egd64d0p